Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.40 |
| ▸ | AURKA | O14965 | 9/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4263125 | 0.91 | CCNA2 (0.43) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6787950 | 0.86 | PARP1 (0.35) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6798826 | 0.85 | IKBKB (0.37) | AURKAPLK1L3MBTL1GSK3B | |
| Trifluoroacetic Acid SCHEMBL4262642 | 0.81 | MAPKAPK2 (0.33) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL4256992 | 0.80 | MAPKAPK2 (0.36) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6794975 | 0.80 | PIM1 (0.36) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL4256994 | 0.80 | MAPKAPK2 (0.36) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL4271434 | 0.80 | PIM1 (0.38) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL4270922 | 0.80 | MAPKAPK2 (0.36) | CDC7 | |
| Trifluoroacetic Acid SCHEMBL4267636 | 0.80 | AR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-9023787-B2 | MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-02-06 | — | — | US | disclosed |
| US-8440610-B2 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120252737-A1 | Methods for Diagnosing and Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090181468-A1 | Methods and compositions for treating cellular proliferative diseases | YAFFE MICHAEL B | 2009-07-16 | — | — | US | disclosed |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-08 | — | — | US | disclosed |
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | MKI67, TP53, CCNC | CCNA2 11/4885CDK2 29/4885CCNA1 9/4885 |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MAPKAPK2, MAPKAP1, MAP3K2 | CCNA2 270/4885CDK2 77/4885CCNA1 327/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MAPKAPK2, MAPKAP1, MAP3K2 | CCNA2 270/4885CDK2 77/4885CCNA1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.